Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach (Q36028631)

11 August 2017

1 reference

title

Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach (English)

1 reference

11 August 2017

1 reference

Peters GJ

1

1 reference

PubMed ID

15688605

11 August 2017

Smorenburg CH

series ordinal

2

1 reference

PubMed ID

15688605

11 August 2017

Van Groeningen CJ

series ordinal

3

1 reference

11 August 2017

1 November 2004

1 reference

11 August 2017

Journal of Chemotherapy

1 reference

11 August 2017

16 Suppl 4

1 reference

11 August 2017

25-30

1 reference

Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil

11 August 2017

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.25

Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.25

Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.25

Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.25

Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.25

Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.25

DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.25

Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.25

Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.25

Polymorphism of the thymidylate synthase gene and thymidylate synthase levels in colon cancer cell lines and different tissues of colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.25

A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.25

Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.25

High-dose 5-Fluorouracil with uridine-diphosphoglucose rescue increases thymidylate synthase inhibition but not 5-Fluorouracil incorporation into RNA in murine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.25

Rapid disappearance of deoxyribose-1-phosphate in platelet derived endothelial cell growth factor/thymidine phosphorylase overexpressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.25

Pharmacogenomics: translating functional genomics into rational therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.25

Enhancement of the antitumor effects of 5-fluorouracil by folinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.25

Clinical relevance of biochemical modulation of 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.25

Comparison of mRNA expression levels determined with TaqMan and competitive template RT-PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.25

Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.25

Irinotecan plus oxaliplatin: a promising combination for advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.25

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2004.16.SUPPLEMENT-1.25

10.1179/JOC.2004.16.SUPPLEMENT-1.25

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15688605